Generic Name and Formulations:
Natamycin 5%; oph susp; contains benzalkonium chloride 0.02%.
Alcon Laboratories, Inc.
Indications for NATACYN:
Treatment of fungal blepharitis, conjunctivitis, and keratitis due to susceptible organisms including Fusarium solani keratitis.
Keratitis: initially 1 drop in the conjunctival sac at hourly or two-hourly intervals. May reduce to 1 drop 6–8 times daily after the first 3–4 days. Continue for 14–21 days or until resolution. Reduce dose gradually at 4–7 day intervals to assure replicating organism is eliminated. Blepharitis, conjunctivitis: less frequent initial dosage (4–6 daily applications) may be sufficient.
Reevaluate if no improvement after 7–10 days. Monitor at least twice weekly; discontinue if drug toxicity occurs. Pregnancy (Cat. C). Nursing mothers.
Conjunctival chemosis and hyperemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib